<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01482117</url>
  </required_header>
  <id_info>
    <org_study_id>10-105</org_study_id>
    <nct_id>NCT01482117</nct_id>
  </id_info>
  <brief_title>The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers</brief_title>
  <official_title>Randomized, Open-label, Crossover Study to Evaluate the Effect of Genetic Polymorphism on Pharmacokinetic &amp; Pharmacodynamic Interactions of Clopidogrel and Cilostazol in Korean Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effects of genetic polymorphisms on
      pharmacokinetic and pharmacodynamic interactions of clopidogrel and cilostazol in Korean
      healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration(Cmax), Area under the concentration(AUC), Inhibition of platelet aggregation(IPA)</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>9 or 11 point blood sampling according to the interventions</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Interaction</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral administration of 300mg of clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilostarole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral administration of 100mg of cilostazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel/Cilostazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral administration of 300mg clopidogrel and 100mg cilostazol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>single oral administration of 300mg of clopidogrel</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Cilostarole</arm_group_label>
    <arm_group_label>Clopidogrel/Cilostazol</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>single oral administration of 100mg cilostazol</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Cilostarole</arm_group_label>
    <arm_group_label>Clopidogrel/Cilostazol</arm_group_label>
    <other_name>Pletaal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel/Cilostazol</intervention_name>
    <description>single oral administration of 300mg clopidogrel and 100mg cilostazol</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Cilostarole</arm_group_label>
    <arm_group_label>Clopidogrel/Cilostazol</arm_group_label>
    <other_name>Plavix/Pletaal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject whose CYP2C19 genotype was determined

        Exclusion Criteria:

          -  Subject who has abnormal laboratory test results
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Gook Shin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2011</study_first_submitted>
  <study_first_submitted_qc>November 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2011</study_first_posted>
  <last_update_submitted>May 31, 2013</last_update_submitted>
  <last_update_submitted_qc>May 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inje University</investigator_affiliation>
    <investigator_full_name>Jae-Gook Shin</investigator_full_name>
    <investigator_title>Department of Pharmacology and Pharmacogenomics Research Center</investigator_title>
  </responsible_party>
  <keyword>CYP2C19</keyword>
  <keyword>CYP3A5</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Cilostazol</keyword>
  <keyword>Healthy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

